vedomostiregmedРегуляторные исследования и экспертиза лекарственных средствRegulatory Research and Medicine Evaluation3034-30623034-3453Federal State Budgetary Institution ‘Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation (FSBI ‘SCEEMP’)vedomostiregmed-36Research ArticleКЛИНИЧЕСКАЯ ФАРМАКОЛОГИЯCLINICAL PHARMACOLOGYЛевосальбутамол - новые возможности лечения бронхиальной астмы (обзор исследований)Levosalbutamol and new opportunities for the treatment of bronchial asthma (review of the related studies)ЛиджиеваА. А.LidzhievaA. A.noemail@neicon.ruСмолярчукЕ. А.SmolyarchukE. A.smolyarchuk@mail.ruНаучно-исследовательский институт фармации Первого Московского государственного медицинского университета им. И.М. СеченоваРоссияResearch Institute of Pharmacy of I.M. Sechenov First Moscow State Medical UniversityRussian Federation201513022018022528Copyright © Лиджиева А.А., Смолярчук Е.А., 20182018Лиджиева А.А., Смолярчук Е.А.Lidzhieva A.A., Smolyarchuk E.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.vedomostincesmp.ru/jour/article/view/36

В обзоре рассматривается новое хирально чистое лекарственное средство - левосальбутамол, предназначенное для лечения бронхиальной астмы. Кратко изложены историческая справка о создании препарата, данные о его фармакологических свойствах и результаты клинических исследований, проводимые как на здоровых добровольцах, так и на пациентах. Представленные данные позволяют сделать выводы о фармакокинетических параметрах препарата, его эффективности и безопасности у пациентов, страдающих бронхиальной астмой.

The review describes the new chirally pure drug - levosalbutamol for the treatment of bronchial asthma. It summarizes historical information about the development of the product, data on its pharmacological properties and the results of clinical trials conducted in healthy volunteers and in patients. The presented data allow to draw conclusions on the drug pharmacokinetic properties, its efficacy and safety in patients suffering from bronchial asthma.

levosalbutamolbronchial asthmaclinical trialsphase I trialssalbutamolлевосальбутамолбронхиальная астмаклинические исследованияисследования I фазысальбутамолReferencesБронхиальная астма. Глобальная стратегия. Пульмонология 1996; Прил. 166.Bronchial asthma. Global Strategy. Pulmonologiya1996; Suppl. 166 (in Russian).Чучалин А.Г. Бронхиальная астма. М.: Агар; 1997.Chuchalin AG. Чучалин АГ. Bronchial asthma. Мoscow: Agar; 1997 (in Russian).Jonson M. ß2-adrenoceptor agonists: optimal pharmacological profile. In: The role of b2-agonists in asthma management. Oxford: The Medicine Group; 1993.Jonson M. β2-adrenoceptor agonists: optimal pharmacological profile. In: The role of b2-agonists in asthma management. Oxford: The Medicine Group; 1993.Авдеев С.Н. Устройства доставки ингаляционных препаратов, используемых при терапии заболеваний дыхательных путей. Российский медицинский журнал 2002; (5): 255-261.Avdeev SN. Inhaled drug delivery device used in the therapy of airway diseases. Rossiyskiy meditsinskiy zhurnal 2002; (5): 255–261 (in Russian).Dhand R., Goode M., Reid R. et al. Preferential pulmonary retention of (S) - albuterol after inhalation of racemic albuterol. Am J Respir Crit Care Med. 1999; 160: 1136-41.Dhand R, Goode M, Reid R, et al. Preferential pulmonary retention of (S) – albuterol after inhalation of racemic albuterol. Am J Respir Crit Care Med. 1999; 160: 1136–41.Prior J.G., Cochrane G.M., Raper S.M., Ali C., Volans G.N. Self-poisoning with oral salbutamol. BMJ 1981; 282: 1932.Prior JG, Cochrane GM, Raper SM, Ali C, Volans GN. Self-poisoning with oral salbutamol. BMJ 1981; 282: 1932.Handley D. The asthma-like pharmacology and toxicology of (S)-isomers of beta agonists. J Allergy Clin Immunol. 1999; 104: S69-S76.Handley D. The asthma-like pharmacology and toxicology of (S)-isomers of beta agonists. J Allergy Clin Immunol. 1999; 104: S69–S76.Drugs@FDA. FDA Approved Drug Products. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm.Drugs@FDA. FDA Approved Drug Products. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm.National Institutes of Health, National Heart, Lung, and Blood Institute. Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. Bethesda, Md: National Institutes of Health, National Heart, Lung, and Blood Institute; April 1997. NIH publication 97-4051.National Institutes of Health, National Heart, Lung, and Blood Institute. Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. Bethesda, Md: National Institutes of Health, National Heart, Lung, and Blood Institute; April 1997. NIH publication 97–4051.Penn R.B., Frielle T., McCullough J.R., Aberg G., Benovic J.L. Comparison of R-, S-, and RS-albuterol interaction with human beta 1- and beta 2-adrenergic receptors. Clin Rev Allergy Immunol 1996; 14: 37-45.Penn RB, Frielle T, McCullough JR, Aberg G, Benovic JL. Comparison of R-, S-, and RS-albuterol interaction with human beta 1- and beta 2-adrenergic receptors. Clin Rev Allergy Immunol 1996; 14: 37–45.Johansson F., Rydberg I., Aberg G. et al. Effects of albuterol enantiomers on in vitro bronchial reactivity. Clin Rev Allergy Immunol 1996; 14: 57-64.Johansson F, Rydberg I, Aberg G, et al. Effects of albuterol enantiomers on in vitro bronchial reactivity. Clin Rev Allergy Immunol 1996; 14: 57–64.Matthew J. Randall, Shannon F. Kostin, Edward J. Burgess, Laura R. Hoyt, Jennifer L. Ather, Lennart K. Lundblad, Matthew E. Poynter. Anti-Inflammatory Effects of Levalbuterol-Induced 11ß-Hydroxysteroid Dehydrogenase Type 1 Activity in Airway Epithelial Cells. Front Endocrinol. 2015 Jan 12; (5): 236.Matthew J. Randall, Shannon F. Kostin, Edward J. Burgess, Laura R. Hoyt, Jennifer L. Ather, Lennart K. Lundblad, Matthew E. Poynter. Anti-Inflammatory Effects of Levalbuterol-Induced 11β-Hydroxysteroid Dehydrogenase Type 1 Activity in Airway Epithelial Cells. Front Endocrinol. 2015 Jan 12; (5): 236.Raffay T., Ko P.( Reynolds J., Di Fiore J., MacFarlane P., Martin R.J. Repeated ß2-adrenergic receptor agonist therapy attenuates the response to rescue bronchodilation in a hyperoxic newborn mouse model. Neonatology 2014; 106(2): 126-32Raffay T, Ko P, Reynolds J, Di Fiore J, MacFarlane P, Martin RJ. Repeated β2-adrenergic receptor agonist therapy attenuates the response to rescue bronchodilation in a hyperoxic newborn mouse model. Neonatology 2014; 106(2): 126–32Johansson F., Rydberg I., Aberg G. et al. Effects of albuterol enantiomers on in vitro bronchial reactivity. Clin Rev Allergy Immunol. 1996; 14: 57-64.Johansson F, Rydberg I, Aberg G, et al. Effects of albuterol enantiomers on in vitro bronchial reactivity. Clin Rev Allergy Immunol. 1996; 14: 57–64.Penn R.B., Frielle T., McCullough J.R., Aberg G., Benovic J.L. Comparison of R-, S-, and RS-albuterol interaction with human beta 1- and beta 2-adrenergic receptors. Clin Rev Allergy Immunol. 1996; 14: 37-45.Penn RB, Frielle T, McCullough JR, Aberg G, Benovic JL. Comparison of R-, S-, and RS-albuterol interaction with human beta 1- and beta 2-adrenergic receptors. Clin Rev Allergy Immunol. 1996; 14: 37–45.Morley J. Anomalous effects of albuterol and other sympathomimetics in the guinea pig. Clin Rev Allergy Immunol. 1996; 14: 65-89.Morley J. Anomalous effects of albuterol and other sympathomimetics in the guinea pig. Clin Rev Allergy Immunol. 1996; 14: 65–89.Lipworth B.J., Clark D.J., Koch P., Arbeeny C. Pharmacokinetics and extrapulmo-nary beta 2 adrenoceptor activity of nebulised racemic salbutamol and its R and S isomers in healthy volunteers. Thorax 1997; 52: 849-52.Lipworth BJ, Clark DJ, Koch P, Arbeeny C. Pharmacokinetics and extrapulmonary beta 2 adrenoceptor activity of nebulised racemic salbutamol and its R and S isomers in healthy volunteers. Thorax 1997; 52: 849–52.Carl J., Myers T., Kercsmar C. Comparison of levalbuterol and racemic albuterol for treatment of acute asthma in pediatric patients [abstract]. Chest 2001; 120(suppl): 137S.Carl J, Myers T, Kercsmar C. Comparison of levalbuterol and racemic albuterol for treatment of acute asthma in pediatric patients [abstract]. Chest 2001; 120(suppl): 137S.Nelson H.S., Bensch G., Pleskow W.W., DiSantostefano R., DeGraw S., Reasner D.S. et al. Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma. J Allergy Clin Immunol. 1998; 102: 943-52.Nelson HS, Bensch G, Pleskow WW, DiSantostefano R, DeGraw S, Reasner DS, et al. Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma. J Allergy Clin Immunol. 1998; 102: 943–52.Gumbhir-Shah K., Kellerman D.J., DeGraw S., Koch P., Jusko W.J. Pharmacokinetics and pharmacodynamics of cumulative single dose of inhaled salbutamol enantiomers in asthmatic subjects. Pulm Pharmacol Ther. 1999; 12(6): 353-62.Gumbhir-Shah K, Kellerman DJ, DeGraw S, Koch P, Jusko WJ. Pharmacokinetics and pharmacodynamics of cumulative single dose of inhaled salbutamol enantiomers in asthmatic subjects. Pulm Pharmacol Ther. 1999; 12(6): 353–62.Jan Lötvall, Mona Palmqvist, Peter Arvidsson, Alan Maloney, Pietro Ventresca, Jonathan Ward. The therapeutic ratio of R-albuterol is comparable with that of RS-albuterol in asthmatic patients. Göteborg, Sweden, and Greenford, United Kingdom. July 27, 2001; S - 413 45 Gothenburg, Sweden.Jan Lötvall, Mona Palmqvist, Peter Arvidsson, Alan Maloney, Pietro Ventresca, Jonathan Ward. The therapeutic ratio of R-albuterol is comparable with that of RS- albuterol in asthmatic patients. Göteborg, Sweden, and Greenford, United Kingdom. July 27, 2001; S-413 45 Gothenburg, Sweden.Kavita Rathore, Tarun Kumar Sharma, M.L. Aseri, Sunil Kumar Mathur, Rakesh Chandra Gupta, Satish Kumar Vardey, G.G. Kaushik, Maheep Sinha. Comparative study of pulmonary functions after administration of albuterol and levalbuterol in patients with moderate to severe bronchial asthma. International Journal of Medicine and Medical Sciences 2012; 4(2): 39-44.Kavita Rathore, Tarun Kumar Sharma, ML Aseri, Sunil Kumar Mathur, Rakesh Chandra Gupta, Satish Kumar Vardey, GG Kaushik, Maheep Sinha. Comparative study of pulmonary functions after administration of albuterol and levalbuterol in patients with moderate to severe bronchial asthma. International Journal of Medicine and Medical Sciences 2012; 4(2): 39–44.

The authors declare that there are no conflicts of interest present.